

MATERIAL CHANGE NOTICE SUBMISSION DETAILS

MCN Number	2026-07-15-1528
OHCA Review Start Date	9/15/2026
Anticipated date (unless tolled per regulation) by which OHCA could waive cost and market impact review	10/30/2026
Anticipated date (unless tolled per regulation) by which OHCA could determine cost and market impact review required	11/14/2026

SUBMITTER

HEALTH CARE ENTITY CONTACT FOR PUBLIC INQUIRY

Title	Vice President
First Name	John
Last Name	Treadwell
Email Address	treadwj@labcorp.com
Street Address	358 South Main Street
City	Burlington
State	North Carolina
Postal Code	27215

GENERAL

Business Name	Laboratory Corporation of America Holdings
Website	labcorp.com
Ownership Type	Corporation
Tax Status	For-profit
Federal Tax ID	13-3757370
Description of Submitting Organization	Laboratory Corporation of America Holdings is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Labcorp provides insights and accelerates innovations to improve health and improve lives through its two business segments: Diagnostic Laboratories and Biopharma Laboratory Services. Business lines or segments: LCAH provides clinical laboratory services and offers a range of frequently requested and specialty testing services, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and

	donor testing, occupational testing services, medical drug monitoring services, chronic disease programs and kidney stone prevention. LCAH's Articles of Incorporation and organizational chart will be provided in the portal.
Health Care Provider	Yes
For Providers: Desc. of Capacity or Patients served in California	The Submitter is a national provider of clinical laboratory services. Submitter owns and operates clinical laboratories in multiple states, and specimens collected from patients in California may be sent for processing to any number of these labs, depending on the type of test ordered. Below is a list of the California-licensed clinical laboratories owned by Submitter that are located in the State of California. Esoterix, Endocrine Sciences Calabasas Hills 4301 Lost Hills Rd, Calabasas Hills, CA 91301 CAP Participant No: 2298301 CLIA Certificate No: 05D0663070 NY PFI 3072 California State CDF-00002343 Integrated Genetics, Sequenom San Diego 3595 John Hopkins Court, San Diego, CA 92121-1121 CAP Participant No: 7527138 CLIA Certificate NO: 05D2015356 NY PFI 5828 California State CDF-00339964 Labcorp / Consumer Genetics Los Angeles 2440 S Sepulveda Blvd, Suite 100, Los Angeles, CA 90064 CAP Participant No: 4187301 CLIA Certificate No 05D0713514 NY PFI 5828 California State CDF-00010226 Labcorp San Diego 13112 Evening Creek Dr South, Suite 200, San Diego, CA 92128 CAP Participant No: 2324301 CLIA Certificate No: 05D0571200 Clinical and Public Health Laboratory License v032025

	Monogram Biosciences San Francisco 345 Oyster Point Blvd, South San Francisco, CA 94080-1913 CAP Participant No: 6909201 CLIA Certificate No: 05D0941934 NY PFI 7318 California State CDF-00011444
--	---

LOCATIONS

Counties	All Counties; Alameda; Alpine; Amador; Butte; Calaveras; Colusa; Contra Costa; Del Norte; El Dorado; Fresno; Glenn; Humboldt; Imperial; Inyo; Kern; Kings; Lake; Lassen; Los Angeles; Madera; Marin; Mariposa; Mendocino; Merced; Modoc; Mono; Monterey; Napa; Nevada; Orange; Placer; Plumas; Riverside; Sacramento; San Benito; San Bernardino; San Diego; San Francisco; San Joaquin; San Luis Obispo; San Mateo; Santa Barbara; Santa Clara; Santa Cruz; Shasta; Sierra; Siskiyou; Solano; Sonoma; Stanislaus; Sutter; Tehama; Trinity; Tulare; Tuolumne; Ventura; Yolo; Yuba
California licenses and numbers	As noted above, Submitter is a national provider of clinical laboratory services, and the California Department of Public Health (DPH) requires all laboratories testing specimens from California to have a California clinical laboratory license. As such, many of Submitter's laboratories both in California and in other states have clinical laboratory licenses issued by the DPH. We have provided the list of clinical labs located in California that are identified on the lab permit as being owned by Submitter, but we do not consider these labs, or other labs that may test specimens associated with the acquired assets, to be "involved in the transaction," nor do we anticipate the transaction affecting the services provided at these labs. Esoterix, Endocrine Sciences Calabasas Hills 4301 Lost Hills Rd, Calabasas Hills, CA 91301

	CAP Participant No: 2298301 CLIA Certificate No: 05D0663070 NY PFI 3072 California State CDF-00002343 Integrated Genetics, Sequenom San Diego 3595 John Hopkins Court, San Diego, CA 92121-1121 CAP Participant No: 7527138 CLIA Certificate NO: 05D2015356 NY PFI 5828 California State CDF-00339964 Labcorp / Consumer Genetics Los Angeles 2440 S Sepulveda Blvd, Suite 100, Los Angeles, CA 90064 CAP Participant No: 4187301 CLIA Certificate No 05D0713514 NY PFI 5828 California State CDF-00010226 Labcorp San Diego 13112 Evening Creek Dr South, Suite 200, San Diego, CA 92128 CAP Participant No: 2324301 CLIA Certificate No: 05D0571200 Clinical and Public Health Laboratory License v032025 Monogram Biosciences San Francisco 345 Oyster Point Blvd, South San Francisco, CA 94080-1913 CAP Participant No: 6909201 CLIA Certificate No: 05D0941934 NY PFI 7318 California State CDF-00011444
Other States Served	None; AK; AL; AR; AZ; CO; CT; DC; DE; FL; GA; HI; IA; ID; IL; IN; KS; KY; LA; MA; MD; ME; MI; MN; MO; MS; MT; NC; ND; NE; NH; NJ; NM; NV; NY; OH; OK; OR; PA; RI; SC; SD; TN; TX; UT; VA; VT; WA; WI; WV; WY
Other state(s) licenses and numbers	LCAH holds laboratory licenses in other states as required by applicable state law.
Primary Languages used when providing services	English

MATERIAL CHANGE

ADDITIONAL ENTITIES

Business Name	Description of the Organization	Ownership Type	Additional MCN Submission
Millennium Health, LLC	See Millennium Submission.	Limited Liability Company	Yes

CRITERIA

A health care entity with annual revenue, as defined in section 97435(d) , of at least \$25 million or that owns or controls California assets of at least \$25 million, or;	Yes
A health care entity with annual revenue, as defined in section 97435(d) , of at least \$10 million or that owns or controls California assets of at least \$10 million and is a party to a transaction with any health care entity satisfying subsection (b)(1), or	Yes
A health care entity located in a designated primary care health professional shortage area in California, as defined in Part 5 of Subchapter A of Chapter 1 of Title 42 of the Code of Federal Regulations (commencing with section 5.1), available at data.hrsa.gov . To determine if you are located in a primary health care professional shortage area, please visit here	No

CIRCUMSTANCES FOR FILING

The proposed fair market value of the transaction is \$25 million or more and the transaction concerns the provision of health care services.	Yes
The transaction is more likely than not to increase annual California-derived revenue of any health care entity that is a party to the transaction by either \$10 million or more or 20% or more of annual California-derived revenue at normal or stabilized levels of utilization or operation.	Yes

TRANSACTION DETAILS

Anticipated Date of Transaction Closure	8/30/2026
Description of the Transaction	By acquiring Millennium, LCAH will improve its ability to provide patients, physicians, and customers greater access to comprehensive, high-quality laboratory services, especially in key complementary clinical drug testing health areas. Pursuant to a Membership Interest Purchase Agreement ("MIPA") dated June 16, 2026, by and among LCAH and Millennium, LCAH will

	acquire 100% of the outstanding non-corporate interests of MH MidCo, LLC. MH MidCo, LLC is a holding company for Millennium, which is a laboratory that specializes in toxicology testing. By acquiring Millennium, LCAH will improve its ability to provide patients, physicians, and customers greater access to comprehensive, high-quality laboratory services, especially in key complementary clinical drug testing health areas. The transaction is necessary and desirable because with the acquisition of Millennium, LCAH will enhance its toxicology offerings and will be able to more effectively compete by utilizing its logistical capabilities to lower costs and deliver superior service quality to customers across the country. The transaction will have a positive public impact as LCAH will be better positioned to provide patients and providers with superior levels of service quality and robust test offerings. The transaction is expected to enhance competition as Millennium's complementary offerings will bolster LCAH's ability to provide superior service levels. There is no expected adverse impact to the public that will result from the transaction as described above. The transaction is expected to close upon receipt of required regulatory clearances.
Submitted to US Department of Justice or Federal Trade Commission?	Yes
Date of Submission	5/28/2026
Description of the Submission	The Parties submitted HSR on May 29, 2026. LCAH pulled its HSR filing on June 30, 2026, and refiled on July 1, 2026.
Submitted to Other Agency?	Yes
Date of Submission	6/11/2026
To Whom Submitted	Indiana Attorney General
Description of Submission (Include Agency name(s) and State(s))	Notice of Healthcare Entity Transaction
Subject to court proceeding	No
Description of current services provided and expected post-transaction impacts on health care services	Tests may be ordered for individuals in all California counties. This will not change as a result of the transaction.

LCAH and its subsidiaries provide laboratory testing services.

- o LCAH's frequently-ordered tests used in regular patient care include blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen (PSA), tests for sexually transmitted diseases (e.g., chlamydia, gonorrhea, trichomoniasis and human immunodeficiency (HIV), and hepatitis C (HCV)), vitamin D, microbiology cultures and procedures, and alcohol and other substance abuse tests.

- o Submitter also offers specialty testing, including gene-based and esoteric testing; advanced tests that target specific diseases and use new technologies; and testing services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention.

- o By acquiring Millennium, LCAH will bolster its existing testing capabilities.

A summary of LCAH patients broken down by age and sex has been uploaded to the portal.

Through The Labcorp Charitable Foundation, a private charitable 501(c)(3) (the "Foundation") LCAH and its affiliates support the mission of bringing quality health care access to all. The Foundation has issued more than 341 grants since 2020 to, among other things, support food pantries and summer meal programs for children, provide access to health care and patient support services for the underserved, broaden access to STEM education programming, and to provide ongoing support for medical research, screenings, and programs that support a healthy lifestyle. The Foundation also matches employee donations to organizations that lead the way in health care research and in equitable access to care such as the American Red Cross, United Way, American

	Diabetes Association, and American Heart Association. - o LCAH offers financial assistance for clinical lab services to patients who qualify for it, based upon the patient's completion of LCAH's application for financial hardship program and provision of supporting documentation. Financial assistance is calculated based on the patient's family size and income as compared to federal poverty income guidelines. - o The Community Health Needs Assessment (CHNA) requirement is not applicable to LCAH. - o Submitter does not anticipate any changes to these programs in connection with the transaction. LCAH provides services for Medi-Cal and Medicare patients and will continue to provide services to these patients post-transaction.
Prior mergers or acquisitions that: (A) involved the same or related health care services; (B) involved at least one of the entities, or their parents, subsidiaries, predecessors, or successors, in the proposed transaction; and (C) were closed in the last ten years.	For LCAH, the following mergers or acquisitions in California were closed in the past ten years: - January 2016 acquisition of Analytical Laboratories - March 2016 acquisition of Pathology Holdings, Inc. - May 2016 acquisition of UWL - Henry Mayo - September 2016 acquisition of Sequenom, Inc. - May 2017 acquisition of PAML - September 2017 acquisition of ChromaDex - October 2018 acquisition of PMI Preclinical - June 2020 acquisition of Rheumatology Diagnostics Lab - October 2020 acquisition of SnaplOT - September 2021 acquisition of Sandstone Diagnostics - March 2024 acquisition of Providence Health & Services Outreach - March 2024 acquisition of WestPac Labs - 2024 acquisition of Invitae - 2024 and 2025 acquisitions of certain assets of BioReference Labs
Description of Potential Post Transaction Changes	LCAH will remove Millennium's officers and directors and will replace these individuals with LCAH's management team. Post-transaction, Millennium will operate as a standalone entity and as a wholly-owned

	subsidiary of LCAH. LCAH intends to retain Millennium's employees, and will maintain their current level of compensation. These employees will transition to LCAH benefits at or shortly after close. LCAH does not expect to make any changes to any city or county contracts. The parties are not aware of any potential post-transaction changes to comparable health services offered by other health care entities within 20 miles of any party location.
Description of the nature, scope, and dates of any pending or planned material changes occurring between the Submitter and any other entity, within the 12 months following the date of the notice	None